Versant Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Versant Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.52K	Buy	359 +129	+56%	+$1.17K	﹤0.01%	2498
2026 Q1	$1.95K	Sell	230 -17	-7%	-$162	﹤0.01%	2572
2025 Q4	$3K	Buy	247 +17	+7%	+$206	﹤0.01%	2379
2025 Q3	$2.69K	Hold	230	–	–	﹤0.01%	2360
2025 Q2	$2.13K	Hold	230	–	–	﹤0.01%	2365
2025 Q1	$1.69K	Hold	230	–	–	﹤0.01%	2289
2024 Q4	$1.96K	Hold	230	–	–	﹤0.01%	2064
2024 Q3	$2K	Buy	+230	New	+$1.9K	﹤0.01%	1562

Other funds holding OCUL

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

RZH

Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Versant Capital Management's OCUL Position: Q2 2026 in Review

Versant Capital Management increased its Ocular Therapeutix (OCUL) stake by 56% in Q2 2026, buying an estimated $1.17K and bringing the position to 359 shares worth $3.52K. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

Versant Capital Management first reported a position in OCUL in Q3 2024 and has held it in 8 quarters since. 22 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Versant Capital Management held 359 shares of Ocular Therapeutix worth $3.52K as of Q2 2026.
Versant Capital Management bought 129 Ocular Therapeutix shares in Q2 2026, an estimated $1.17K.
Ocular Therapeutix made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2498 holding.
Versant Capital Management first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 8 quarters since.
22 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.